Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide With or Without Obatoclax Administered Every 3 Weeks to Patients With Extensive- Stage Small Cell Lung Cancer (ES-SCLC)

NCT00682981 is registered in ClinicalTrials.gov with Gemin X as lead sponsor.

NCT NCT00682981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00682981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide With or Without Obatoclax Administered Every 3 Weeks to Patients With Extensive- Stage Small Cell Lung Cancer (ES-SCLC)
Lead sponsor
Gemin X
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2008
Completion date
November 30, 2011
Enrollment
218 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small cell lung cancer